IGI reports phase 1 results of ISB 2001 trispecific antibody in relapsed or refractory multiple… EP News Bureau Jun 4, 2025 TRIgnite-1 study shows 79 per cent response rate and no dose-limiting toxicities in early-stage trial of BCMA × CD38 × CD3…
